Manufacturers

First 10 drugs for Medicare price negotiation announced under IRA

Manufacturers

The cures conundrum: The importance of getting value assessment right for transformational therapies

Manufacturers

VPAS—Where next?

Manufacturers

On-demand webinar: The EU JCA process: Opportunities and challenges in bringing innovative medicines to patients in Europe

Issue Brief: Assessing the impact of formulary exclusion on healthcare costs and outcomes for patients on therapy for certain chronic conditions

Medicare cannot age in place: A diversifying population requires policy evolution

Manufacturers

New pan-EU HTA: How can biopharma navigate the joint clinical assessment?

The biosimilars marketplace: Part one

Skyrocketing growth in PBM formulary exclusions continues to raise concerns about patient access

Medicaid Best Price and Its Implications on Cell and Gene Therapy Products

Joint clinical assessment in the EU: Pan-European HTA for drugs and medical devices will become reality 

Accelerated approval not accelerated access: Clinical trials required for coverage of Alzheimer's treatments

Health disparities and health technology assessment: Current value assessment frameworks fall short

HTA Quarterly | Fall 2021

Equity considerations in US value assessment: Opportunities ahead

Affordability is about more than drug prices

Copay accumulators and the impact on patients

Patient-Centered Cost Outcomes—Addressing a Gap in Value Assessment

Let's Ditch 2020 and Plan for 2021: Election What-Ifs

Impact of First Dollar Coverage for Insulin

Medicaid's Proposed “Line Extension” Redefinition Imperils Innovation and Patient Access

Therapeutic Spotlight: New Evidence Brings Cautious Optimism to Alzheimer’s Disease Treatment

Potential Access Implications of a National Formulary in Part D

Webinar: Navigating Pre-approval Information Exchange (PIE) and the AMCP Format for Formulary Submissions, Version 4.1

Impact of COVID-19 Pandemic on Patient Access Programs

Integration of Patient-Reported Outcomes (PROs) and the Patient Voice: A Review of 6 Health Technology Assessment (HTA) Agencies

Making Part D Access Affordable: Revising the Prescription Drug Benefit

Manufacturers

Mind the (Evidence) Gap

Effectively Communicating Pipeline Information to Drive Payers Attention

The Evolving Healthcare Landscape and the Impact on Patient Access and Affordability

Manufacturers

Managing the Growing Expansion of Copay Accumulators

Original Report: Impact Analysis of ICER Formulary Implementation in Medicaid

Xcenda Collaborated with MAPRx to Publish New Report Addressing Medicare Part D Challenges to Beneficiaries

Emerging Trends in PBM Restrictions on Commercial Copay Assistance

Applying Cost-Effectiveness Thresholds to the Real World: Implications on Access for Medicare Beneficiaries

Manufacturers

Seeing the Value and Transparency of Medicare Part B

Xcenda Examines the Impact of the Tax Cuts and Jobs Act on the Life Science Sector

Finding the Balance in Pharmaceutical Evidence Exchange With Payers and Providers

Xcenda Conducts Unique Research on Air Medical Services Costs

Analyzing the impact of Medicare Part D for Oncology Patients

Part B Drug Payment Change: Understanding the Implications for Pharma